News
Localising and automating supply chains will allow companies to mitigate the impact of tariffs and minimise resulting costs.
Following today’s release of DFS’ figures for the 52 weeks ending 29 June 2025; Matt Walton, senior retail analyst at ...
Grenke has become the 40th organisation to join Acquis Lumia, an industry-wide register of asset finance borrowing created to ...
The success of the post-growth model is reliant on transparency, clear and honest communication with customers and supplier collaboration.
10h
Mining Technology on MSNCanada introduces new steel tariffs to protect domestic steel industryEffective from 1 August 2025, the quota will apply to countries with which Canada has free trade agreements, excluding the US ...
Walmart and its banking partner Mastercard have created a new payment system for international money transfers, data ...
8h
Clinical Trials Arena on MSNAstraZeneca’s AL amyloidosis drug fails to impress in Phase III"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Experian (EXPN), Barratt Redrow (BTRW), B&M European Value (BME), GlobalData (DATA), Robert Walters (RWA), Mobico (MCG), ...
7d
Pharmaceutical Technology on MSNCTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031The US dominates overall sales, yet GlobalData predicts that China is shaping up to be a formidable presence in the cell therapy space.
6d
GlobalData on MSNNvidia’s historic $4 trillion market cap highlights AI chip sectorAccording to GlobalData’s Innovation Radar report, “AI Chips – Trends, Market Dynamics and Innovations,” the global AI chip ...
2d
Medical Device Network on MSNMedtronic’s Hugo robot wins CE mark for vessel-sealing technologyMedtronic has secured EU CE mark approval for LigaSure RAS, a vessel-sealing instrument for use with the company’s Hugo robotic-assisted surgery (RAS) system.
6d
GlobalData on MSNPfizer and Astellas’ Xtandi improves OS as combination therapyPfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results